Have you started testing your patients with MBC for germline BRCA mutations? BRCA testing is important to guide treatment with PARP inhibitors.
Do you have questions about using PARP inhibitors as effectively as possible to treat your patients with breast cancer? Read expert answers to key questions from the audience at a recent symposium on PARP inhibition.
Are you curious about the next steps with PARP inhibitors for patients with breast cancer?
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.